Preclinical study shows oral PL7737 agonist outperforms tirzepatide alone in rodent models, supporting Palatin’s plans for ...

Anti-diabetic and obesity drug, tirzepatide induced weight loss in obese mice and reduced growth of breast cancer tumors. | ...

In postmenopausal women with overweight or obesity receiving tirzepatide, use of menopausal hormone therapy (MHT) is associated with superior weight loss outcomes, according to a study presented at ...

For adults with obesity treated with once-weekly tirzepatide, cardiometabolic risk factor improvements were positively ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with the degree of weight reduction.

Hidden health benefits from weight-loss jabs revealed - The study saw experts from Taiwan examine data on 60,000 people from around the world ...

Oral PL7737 monotherapy produced rapid and significant weight loss after just 4 days of treatment Combination of oral PL7737 and tirzepatide resulted in additive ...

Researchers found that pairing tirzepatide with hormone therapy boosts weight loss success in postmenopausal women—up to 17% total body weight lost.

Hengrui has reported topline data from the 301 study of their dual GLP-1 and GIP agonist HRS9531, administered as a ...

Oral PL7737 monotherapy produced rapid and significant weight loss after just 4 days of treatmentCombination of oral PL7737 ...